Gero is a physics-enabled biotechnology company focused on developing therapeutics aimed at addressing chronic diseases and slowing the aging process. The company employs Large Health Models (LHMs), which utilize longitudinal real-world human data and unsupervised training methods to predict future health outcomes. These models are distinct from traditional machine learning approaches, as they are physics-based and fully interpretable, allowing for a deeper understanding of the underlying mechanisms of aging and age-related diseases. By integrating genetic data with LHMs, Gero aims to uncover new treatment options and improve patient stratification for chronic conditions.

In addition to its innovative modeling techniques, Gero actively collaborates with pharmaceutical companies, such as Pfizer, to identify potential therapeutic targets for diseases with significant unmet needs, like fibrotic diseases. This collaborative approach leverages Gero's platform technology alongside the extensive expertise of established biopharmaceutical firms, enhancing the potential for discovering high-value targets in the realm of aging and chronic disease treatment. Through these efforts, Gero is positioned at the forefront of longevity biotechnology, striving to revolutionize the understanding and management of aging and its associated health challenges.

Singapore

We are a preclinical stage AI drug discovery company with a mission to eliminate age-related diseases

We use AI to build clinically relevant disease phenotypes in real-world human data and identify diseases with shared biology. Then WES-enabled genetic study on these phenotypes allows us to discover novel targets applicable to several indications at once.

You can find our publications here: https://gero.ai/publications

Gero

Company Details